rss
J Neurol Neurosurg Psychiatry 1985;48:157-159 doi:10.1136/jnnp.48.2.157
  • Research Article

Intravenous methylprednisolone for multiple sclerosis in relapse.

  1. M P Barnes,
  2. D E Bateman,
  3. P G Cleland,
  4. D J Dick,
  5. T J Walls,
  6. P K Newman,
  7. M Saunders,
  8. P J Tilley

      Abstract

      A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.

      This Article

      1. Abstract
      2. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

      BMJ Careers - Latest neurology and neurosurgery jobs